Reference is made to the previous stock exchange announcement from SoftOx Solutions AS (the "Company" or "SoftOx", ticker SOFTX) on 4 January 2021 regarding the Company's extraordinary general meeting resolving tranche 2 in the previously announced private placement.
The share capital increase pertaining to tranche 2 in the private placement of NOK 8,181.80 divided on 409,090 shares has today been registered in the Norwegian Register of Business Enterprises (Nw: Foretaksregisteret).
Following the share capital increase, the new share capital in the Company is NOK 174,779.80 divided into 8,738,990 shares, each with a nominal value of NOK 0.02.
The new shares will be listed and tradable on Euronext Growth Oslo from issuance in the Central Securities Depository (VPS).
For further information, please contact:
Geir Almås, CEO of SoftOx Solutions AS
Mail: geir.almaas@soft-ox.com
Mobile: +47 977 59 071
About SoftOx Solutions AS
SoftOx Solutions AS (SoftOx, listed on the Oslo Stock Exchange Euronext Growth) is a Norwegian MedTech company based in Oslo with the aim of helping to combat major threats to human health, namely the emergence of antimicrobial resistance (AMR), biofilm infections in chronic wounds and the spread of viruses. For more information on SoftOx, visit www.soft-ox.com